Drug Resistance

Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)


Normal cells and tissues are provided with selective means to protect them against endogenous substances produced in excess in the body or against toxic exogenous substances.


Multidrug Resistance Human Breast Cancer Cell Glutathione Transferase Chinese Hamster Cell Acquire Drug Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Young CW, Schochetman G, Karnofsky DA: Hydroxy urea-induced inhibition of deoxyribonucleotide synthesis: studies in intact cells. Cancer Res 1967 (27): 526–534PubMedGoogle Scholar
  2. 2.
    Choy BK, McClarty GA, Chan AK, Thelander L, Wright JA: Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations. Cancer Res 1988 (48): 2029–2035PubMedGoogle Scholar
  3. 3.
    McClarty GA, Chan AK, Engstrom Y, Wright JA, Thelander L: Elevated expression of M1 and M2 components and drug-induced post transcriptional modulation of ribonuleotide reductase in a hydroxyurea resistant mouse cell line. Biochemistry 1987 (26): 8004–8011PubMedCrossRefGoogle Scholar
  4. 4.
    Alt FW, Kellems FR, Bertino JR, Schimke RT: Selective multiplication of dihydrofolate reductase gene in methotrexate-resistant variants of cultured murine cells. J Biol Chem 1978 (253): 1357–1370PubMedGoogle Scholar
  5. 5.
    Schimke RT: Gene amplification, drug resistance, and cancer. Cancer Res 1984 44: 1735–1742PubMedGoogle Scholar
  6. 6.
    Fox M, Roberts JJ: Drug resistance and DNA repair. Cancer and Metastasis Rev 1987 (6): 261–281CrossRefGoogle Scholar
  7. 7.
    Heck MMS, Hittelman WN, Earnshaw WC: Differential expression of DNA topoisomerase I and Il during the enkariotic cell cycle. Proc Natl Acad Sci USA 1988 851086–1090Google Scholar
  8. 8.
    Hsiang YH, Wu HY, Liu LF: proliferation-dependent regulation of topoisomerase II in cultured human cells. Cancer Res 1988 (48): 3230–3235PubMedGoogle Scholar
  9. 9.
    Trask DK, Muller: Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc Natl Acad Sci USA 1988 (85): 1417–1421PubMedCrossRefGoogle Scholar
  10. 10.
    Rowe TC, Chen GL, Hsiang YH, Liu LF: DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res 1986 (46): 2021–2026PubMedGoogle Scholar
  11. 11.
    Pommier Y, Schwartz RE, Zwelling LA, Kerrigan D, Mattem MR, Charcosset JY, Jacquemin-Sablon A, Kohn KW: Reduced formation of protein associated DNA strand breaks in chinese hamster cells resistant to topoisomerase II action. Cancer Res 1986 (46): 611–616PubMedGoogle Scholar
  12. 12.
    Zwelling LA, Estey E, Silberman L, Doyle S, Hittelman W: Effect of cell proliferation and chromatin conformation of intercalator–induced protein associated DNA cleavage in human brain tumor cells and human fibrobalsts. Cancer Res 1987 (47): 251–257PubMedGoogle Scholar
  13. 13.
    Bakic M, Chan D, Freireich EJ, Marton LJ, Zwelling LA: Effect of polyamine depletion by Difluoromethylornithine or 2R,5R-6-heptyne-2,5diamine on drug induced topoisomerase Il-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells. Cancer Res 1987 (47): 6437–6443PubMedGoogle Scholar
  14. 14.
    Pommier Y, Kerrigan D, Schwartz RE, Swack JA, McCendy A: Altered DNA topoisomerase II activity in chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 1986 (46): 3075–3081PubMedGoogle Scholar
  15. 15.
    Pommier Y, Kerrigan D, Covey JM, Kao-Shan CS, Wang-Peng J: Sister chromatide exchanges, chromosomal aberrations and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive DC 3F and resistant DC 3F/9-DHE chinese hamster cells. Cancer Res 1988 (48): 512–516PubMedGoogle Scholar
  16. 16.
    Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KFJ: Over expression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986 (261): 15544–15549PubMedGoogle Scholar
  17. 17.
    Richon VM, Schulte N, Eastman A: Multiple mechanisms of resistance to cisdiamminedichloroplatinum II in murine leukemia L1210 cells.Cancer Res 1987(47): 2056–2061Google Scholar
  18. 18.
    Wang AL, Tew KD: Increased glutathione Stransferase acticity in a cell line with acquired resistance to nitrogen mustard. Cancer Treat Rep 1985 (69): 677–682PubMedGoogle Scholar
  19. 19.
    Deffie AM, Alam T, Senevriatne C, Beenken SW, Batra JK, Shea TC, Henner WD, Goldenberg GJ: Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux and P-glycoprotein in cloned cell line of adriamycin-sensitive and -resistant P 388 leukemia. Cancer Res 1988 (48): 3595–3602PubMedGoogle Scholar
  20. 20.
    Kano T, Sakai M, Muramatsu M: Structure and expression of a human class t glutathione Stransferase messenger RNA. Cancer Res 1987 (47): 5626–5630PubMedGoogle Scholar
  21. 21.
    Tatematsu M, Mera Y, Ito N, Satoh K, Sato K: Relative merits of immunohistochemical demonstration of placental A,B and C forms of glutathione S-Transferase and histochemical demonstration of g-glutamyltransferase as marker of altered foci during liver carcinogenesis of rat. Carcinogenesis 1985 (6): 1621–1626PubMedCrossRefGoogle Scholar
  22. 22.
    Dejong JL, Morgenstern R, Jornvall H, Depierre JW, Tu CPD: Gene expression of rat and human microsomal glutathione transferase. J Biol Chem 1988 (263): 8430–8436PubMedGoogle Scholar
  23. 23.
    Rushmore TH, Harris L, Nagai M, Sharma RN, Hayes MA, Cameron RG, Murray RK, Farber E: Purification and characterization of P-52 Glutathione S.Transferase-P or 7–7 from normal liver and putative preneoplastic liver nodules. Cancer Res 1988 (48): 2805–2812PubMedGoogle Scholar
  24. 24.
    Kirkpatrick DL: Modification of antitumor disulfide cytotoxicity by glutathione depletion in murine cells. Cancer Res 1987 (47): 4391–4395PubMedGoogle Scholar
  25. 25.
    Green JA, Vistica DT, Young RC, Hamilton TL, Rogan AM, Ozols RF:Potentiation of melfalan cytotoxicity in human ovarian cell lines by glutathione depletion. Cancer Res 1984 (44): 5427–5431PubMedGoogle Scholar
  26. 26.
    Russo A, Graff W, Friedman N, Mitchell JB: Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res 1986 (46): 2845–2848PubMedGoogle Scholar
  27. 27.
    Kramer RA, Greene K, Ahmad S, Vistica DT: Chemosensitization of L-Phenylalanine mustard by the thiol-modulating agent buthionine-sulfoximine. Cancer Res 1987 (47): 1593–1597PubMedGoogle Scholar
  28. 28.
    Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM, Pastan I: Single cell analysis of daunomycine uptake and efflux in multidrugresistant and sensitive KB cells: effects of Verapamil and other drugs.Cancer Res 1986 (46): 5941–5946PubMedGoogle Scholar
  29. 29.
    Fojo A, Akiyama SI, Gottesman MM, Pastan I: Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res 1985 (45): 3002–3007PubMedGoogle Scholar
  30. 30.
    Siegfried JA, Kennedy KA, Sartorelli AC, Tritton TR: The role of membranes in the mechanism of action of the antineoplastic agent adriamycin. J Biol Chem 1983 (10): 339–343Google Scholar
  31. 31.
    Cornwell MM, Gottesman MM, Pastan IH: Increased vinblasine binding to membrane vesicles from multidrug resistant KB cells. J Biol Chem 1986 (261): 7921–7928PubMedGoogle Scholar
  32. 32.
    Kartner N, Riordan JR, Ling V: Cell surface Pglycoprotein associated with multidrug resistance in mammalian cell line’s. Science 1983 (221): 1285–1288PubMedCrossRefGoogle Scholar
  33. 33.
    Shen D, Cardarelli C, Hwang J, Cornwell M, Richert N, Ishii S, Pastan I, Gotteman MM: Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin or vinblastine show changes in expression of specific proteins.J Biol Chem 1986 (261): 7762–7770PubMedGoogle Scholar
  34. 34.
    Gerlach JH, Endicott JA, Juranka PF, Henderson G, Sarangi F, Deuchers KL, LingHomology between Pglycoprotein and a baterial hemolysin transport protein suggest a mode for multidrug resistance. Nature 1986 (324): 485–489PubMedCrossRefGoogle Scholar
  35. 35.
    Shen DW, Fojo A, Roninson JB, Chin R, Soffir R, Pastan I, Gottesman MM: Multidrug resistance of DNA-mediated transformants in linked to transfer of the human mdrl gene. Mol Cell Biol 1986 (6): 4039–4034PubMedGoogle Scholar
  36. 36.
    Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V: Amplification of P-glycoprotein genes in multigrug-resistant mammalian cell lines. Nature 1985 (232): 817–81CrossRefGoogle Scholar
  37. 37.
    Gros P, Groop J, Roninson L, Varshaysky A, Housman DE: Isolation and characterization of DNA sequences amplified in multidrug resistant hamster cells. Proc Natl Acad Sci USA 1986 (83):337–34PubMedCrossRefGoogle Scholar
  38. 38.
    Sugimoto Y, Tsuruo T: DNA-mediated transfer and cloning of a human multidrug resistant gene of adriamycin-resistant myelogenous leukemia K562. Cancer Res 1987 (47): 2620–2625PubMedGoogle Scholar
  39. 39.
    Shen D, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, Gottesman MM: Human multidrug-resistant cell lines: increased mdrl expression can precede gene amplification. Science 1986 (232): 643–645PubMedCrossRefGoogle Scholar
  40. 40.
    Shen DW, Pastan I, Gottesman MM: In situ hybridation analysis of acquisition and loss of the human multidrug-resistant gene. Cancer Res 1988 (48): 4334–4339PubMedGoogle Scholar
  41. 41.
    Biedler J, Reihm H, Peterson R, Spengler BA: Membrane mediated drug resistance and phenotypic reversion to normal growth behavior chinese hamster cells. J Natl Cancer Inst 1975 (55): 671–680PubMedGoogle Scholar
  42. 42.
    Hill AB, Beck WT, Trent JM: Cytogenetic and molecular characterization of tumors in mdr mice derived from a multidrug resistant human leukemia cell line. Cancer Res 1988 (48): 393–398PubMedGoogle Scholar
  43. 43.
    Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan O: Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987 (84): 265–269PubMedCrossRefGoogle Scholar
  44. 44.
    Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987 (84): 7735–7738PubMedCrossRefGoogle Scholar
  45. 45.
    Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsurudo T, Itoyama S, Mori S: Tissue distribution of P-glycoprotein encoded by a multidrug resistant gene as revealed by monoclonal antibody-MRK 16. Cancer Res 1988 (48): 1926–1929PubMedGoogle Scholar
  46. 46.
    Klohs WD, Steinkampf RW: Possible link between the intrinsic drug resistance of colon tumors and a detoxification mechanism of intestinal cells. Cancer Res 1988 (48): 3025–3030PubMedGoogle Scholar
  47. 47.
    Sager R, Gadi IK, Stephens L, Grabowy CT: Gene amplification: an example of accelerated evolution in tumourigenic cells. Proc Natl Acad Sci USA 1985 (82): 7015–7019PubMedCrossRefGoogle Scholar
  48. 48.
    Cowan KH, Batist G, Tulpule A, Sinha BK, Myers CE: Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci USA 1986 (83): 9328–9332CrossRefGoogle Scholar
  49. 49.
    Fairchild CR, Ivy SP, Rushmore T, Lee G, Kod P, Goldsmith ME, Myers CE, Farber E, Cowan KH: Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic nodules and hepatocellular carcinomas. Proc Natl Acad Sci USA 1987 (84): 7701–7705PubMedCrossRefGoogle Scholar
  50. 50.
    Thorgeirsson SS, Huber BE, Sorrell S, Fojo A, Pastan I, Gottesman MM: Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 1987 (236): 1120–1122PubMedCrossRefGoogle Scholar
  51. 51.
    Cifone MA, Fidler IJ: Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Mad Sci USA 1981 (78): 6949–6952CrossRefGoogle Scholar
  52. 52.
    McGrath T, Center MS: Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res 1988 (48): 3959–3963PubMedGoogle Scholar
  53. 53.
    Van der Blieck AM, Baas F, Ten Houte de Lange T, Kooiman PM, Van der Velde-Koerts T, Borst P: The human mdr 3 genes encodes a novel P-glycoprotein homologue and gives rise to alternatively mRNA in the liver. The Embo Journal 1987 (6): 3325–3331Google Scholar
  54. 54.
    Dalton WS, Cress AE, Alberts DS, Trent JM: Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res 1988 (48): 1882–1888PubMedGoogle Scholar
  55. 55.
    Fairchild CR, Ivy SP, Kad-Shan CS, Whang-Peng J, Rosen N, Israel MA, Melera PW, Cowan KH, Goldsmith ME: Isolation of amplified over expressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 1987 (47): 5141–5148PubMedGoogle Scholar
  56. 56.
    Fojo A, Lebo R, Shimizu N, Chin JE, Roninson IB, Merlino GT, Gottesman MM, Pastan I: Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somatic Cell Mol Genet 1986 (12): 415–420CrossRefGoogle Scholar
  57. 57.
    Slovak ML, Hoeltge GA, Trent JM: Cytogenetic alterations associated with the acquisition of Doxorubicin resistance: possible significance of chromosomes 7 alterations. Cancer Res 1987 (47): 6646–6652PubMedGoogle Scholar
  58. 58.
    Meyers MB, Biedler J: Increased synthesis of low molecular weight protein in vincristine-resistant cells. Biochem Biophys Res Commun 1981 (99): 228–235PubMedCrossRefGoogle Scholar
  59. 59.
    Koch G, Smith M, Twentyman P, Wright K: Identification of a novel calcium-binding protein CP22 in multidrug-resistant murine and hamster cells. FEBS Lett 1986 (195): 275–279PubMedCrossRefGoogle Scholar
  60. 60.
    Hamada H, Okochi E, Oh-Hara T, Tsuruo T: Purification of the M2 22,000 calcium-binding protein Sorcin associated with multidrug resistance and its detection with monoclonal antibodies. Cancer Res 1988 (48): 3173–3178PubMedGoogle Scholar
  61. 61.
    Fuqua SAW, Moretti-Rojas IM, Schneider SL, McGuire WL: P-glycoprotein expression in human breast cancer cells. Cancer Res 1987 (47): 2103–210PubMedGoogle Scholar
  62. 62.
    Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y: Overcoming of vincristine resistance in P 388 leukemia in vivo in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981 (141): 1967–1972Google Scholar
  63. 63.
    Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL, Felsted RL: Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J. Biol Chem 1987 (262): 7884–7888PubMedGoogle Scholar
  64. 64.
    Cornwell MM, Pastan I, Gottesman MM: Certain calcium channel blockers bind specifically to multidrug human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 1987 (262): 2166–2170PubMedGoogle Scholar
  65. 65.
    Mellado W, Horwitz SB: Phosphorylation of the multidrug resistance associated glycoprotein. Biochem 1987 (26): 6900–6904CrossRefGoogle Scholar
  66. 66.
    Hamada H, Hagiwara K, Nakajima T, Tsuruo T: Phosphorylation of the M2 170,000 to 180,000 glycoprotein specific of verapamil, trifluoroperazine and phorbol esters. Cancer Res 1987 (47): 2860–2868PubMedGoogle Scholar
  67. 67.
    Hamada H, Tsuruo T: Characterization of the ATPase activity of the M2 170,000 to 180,000 membrane glycoprotein P-glycoprotein associated with multidrug resistance in K562/ADM cells. Cancer Res 1988 (48): 4926–4932PubMedGoogle Scholar
  68. 68.
    Ramu A, Glaubiger D, Fuks Z: Reversal of acquired resistance to doxorubicin in P 388 murine leukemia cells by tamoxifen and other triparanol analogs. Cancer Res 1984 (44): 4392–4395PubMedGoogle Scholar
  69. 69.
    Hindenburg A, Baker MA, Gleyzer E, Stewart VJ, Case N, Taub RN: Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance. Cancer Res 1987 (47): 1421–1425PubMedGoogle Scholar
  70. 70.
    Tsuruo T, Iida H, Tsukagoshi S, Sakenai Y: Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 1983 (43): 2267–2272PubMedGoogle Scholar
  71. 71.
    Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y: Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 1983 (43): 2905–2910PubMedGoogle Scholar
  72. 72.
    Ganapathi R, Grabowski D: Enhancement of sensitivity of adriamycin in resistant P 388 leukemia by the calmodulin inhibitor trifluoroperazine.Cancer Res 1983 (43): 3636–363Google Scholar
  73. 73.
    Fine RL, Patel J, Chabner BA: Phorbol esters induce multidrug Resistance in human breast cancer cells. Proc Natl Acad Sci USA 1988 (85): 582–586PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • S. Saez
    • 1
  1. 1.Centre Leon BerardLyon Cedex 08France

Personalised recommendations